VJOncology is committed to improving our service to you

ESMO 2016 | Pembrolizumab and the significance of PD-L1 for lung cancer

VJOncology is committed to improving our service to you

Roy Herbst

Roy Herbst, MD, PhD of Yale School of Medicine, New Haven, CT talks about pembrolizumab and the importance of the PD-L1 biomarker. Prof. Herbst explains that the biomarker does help discriminate patients who will benefit most from the drug. He further explains that patients should now be tested for PD-L1 at diagnosis and those who are PD-L1 positive will receive pembrolizumab and those who are PD-L1 negative will receive other treatment.
Recorded at the 2016 annual meeting of the European Society of Medical Oncology (ESMO), held in Copenhagen, Denmark.

Share this video  

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter